- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02017899
A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
A Phase 1, Randomized, Observer Blinded, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Intramuscularly in Healthy Adults.
This Phase 1 clinical trial is aimed to evaluate the safety and immunogenicity of 3 doses of 5 sequentially escalating dosages of a candidate vaccine against Shigella sonnei (1790GAHB vaccine) administered by intramuscular route in healthy adults (18 to 45 years of age at enrollment). The safety profile of the 1790GAHB vaccine is evaluated in comparison to that of placebo (GAHB-Placebo), constituted by an aluminum hydroxide suspension having the same concentration as study vaccine formulations. A total of 50 eligible subjects will be assigned to one of five sequential cohorts of 10 subjects each.
Within each cohort, in an observer-blind fashion, subjects will be randomized to receive three vaccinations, four weeks apart, of either 1790GAHB vaccine (at five antigen concentrations) or GAHB placebo. A Data Safety Monitoring Board will be in place to receive a summary of all safety data obtained during one week follow-up post-first vaccination with the lower dose. Based on evaluation of the safety data, the Data Safety Monitoring Board will make a recommendation, as to whether the next cohort should be vaccinated with higher antigen concentration or not.
Expected duration of the study for an individual subject is 9 months. Each subject will be followed-up for 6 months after the 3rd vaccination.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Paris Cedex 14
-
Paris, Paris Cedex 14, France, 75679
- Centre d'Investigation Clinique en Vaccinologie Cochin-Pasteur (CIC1417)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females of age ≥18 years to ≤45 years.
- Individuals who, after the nature of the study has been explained to them, and prior to any protocol specific procedures being performed, have given written consent according to local regulatory requirements.
- Individuals in good health as determined by the outcome of medical history, physical examination, hematological / hematochemical blood tests (including presence of high antibody titers against S. sonnei by agglutination test), urinalysis and clinical judgment of the investigator.
- If women of child-bearing potential, have a negative pregnancy test prior study vaccination and willingness to use acceptable birth control measures for the entire study duration.
- Individuals affiliated to a social security regimen.
Exclusion Criteria:
- Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
- Individuals with any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.
- Individuals who are not able to understand and to follow all required study procedures for the whole period of the study.
- Individuals with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
- Individuals human leukocyte antigen (HLA) -B27 positive and/or with history of reactive arthritis.
- Individuals with known or suspected HIV infection or HIV related disease, with history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids (i.e. prednisone, or equivalent ≥10 mg/day) within the previous 28 days, or in chemotherapy treatment within the past 168 days.
- Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- Individuals with any serious chronic or progressive disease according to judgment of the investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
- Individuals who have any malignancy or lymphoproliferative disorder.
- Individuals with history of allergy to vaccine components.
- Individuals participating in any clinical trial with another investigational product 28 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.
- Individuals who received any other vaccines within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine within the entire study duration except influenza vaccination, which is not allowed within the period included between 28 days before 1st vaccination and 28 days after 3rd vaccination.
- Individuals who have received blood, blood products, and/or plasma derivatives including parenteral immunoglobulin preparations in the past 12 weeks.
- Individuals who are part of study personnel or close family members to the personnel conducting this study or employees of the clinical trial site institution.
- Individuals with body temperature > 38.0 degrees Celsius within 3 days of intended study vaccination.
- Individuals with Body Mass Index (BMI)> 30 kg/m2
- Individuals with history of substance or alcohol abuse within the past 2 years.
- Women who are pregnant or are breast-feeding, or are of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study.
- Females with history of stillbirth, neonatal loss, or previous infant with anomaly.
- Individuals who have a previously laboratory confirmed or suspected disease caused by S. sonnei.
- Individuals who have had household contact with/and or intimate exposure to an individual with laboratory confirmed S. sonnei.
- Any condition, which, in the opinion of the investigator may pose an increased and unreasonable safety risk to the subject if participating to the present study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: S. sonnei 1790GAHB - 1 mcg
Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 1 mcg
|
Other Names:
|
Experimental: S. sonnei 1790GAHB - 5 mcg
Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 5 mcg
|
Other Names:
|
Experimental: S. sonnei 1790GAHB - 25 mcg
Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 25 mcg
|
Other Names:
|
Experimental: S. sonnei 1790GAHB - 50 mcg
Subjects enrolled in COHORT D receiving 3 injections of S. sonnei 1790GAHB - 50 mcg
|
Other Names:
|
Experimental: S. sonnei 1790GAHB - 100 mcg
Subjects enrolled in COHORT E receiving 3 injections of S. sonnei 1790GAHB - 100 mcg
|
Other Names:
|
Placebo Comparator: Placebo
2 subjects enrolled in each COHORT A, B, C, D, E receiving 3 injections of Placebo.
These were pooled in one Placebo group in the analyses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Solicited Local Reaction After Any Vaccination
Time Frame: During a 7-day (Days 1-7) post vaccination period following any injection
|
Any erythema/induration refers to: ≥25 mm in diameter.
Grade 3 (severe) refers to erythema/induration >100 mm in diameter.
Grade 3 (severe) for injection site pain refers to: prevents daily activity
|
During a 7-day (Days 1-7) post vaccination period following any injection
|
Number of Subjects With Solicited Systemic Reaction After Any Vaccination
Time Frame: During a 7-day (Days 1 to 7) post vaccination period following any injection
|
Any= Incidence of any symptom regardless of intensity grade.
Grade 3 = symptom that prevented daily activities
|
During a 7-day (Days 1 to 7) post vaccination period following any injection
|
Number of Subjects With Neutrophils Results Below and Above the Normal Ranges
Time Frame: At Day 8
|
Day 8: VISIT 2 (D7 post 1st vac)
|
At Day 8
|
Number of Subjects With Neutrophils Results Below and Above the Normal
Time Frame: At Day 36
|
Day 36: VISIT 3.1 (D7 post 2nd vac.)
|
At Day 36
|
Number of Subjects With Neutrophils Results Below and Above the Normal
Time Frame: At Day 57
|
Day 57: VISIT 4 (3rd vac.)
|
At Day 57
|
Number of Subjects With Neutrophils Results Below and Above the Normal
Time Frame: At Day 64
|
Day 64: VISIT 4.1 (D7 post 3rd vac.)
|
At Day 64
|
Number of Subjects With Neutrophils Results Below and Above the Normal
Time Frame: At Day 85
|
Day 85: VISIT 5 (1 month post 3rd vac.)
|
At Day 85
|
Number of Subjects With Neutrophils Results Below and Above the Normal
Time Frame: At Day 225
|
Day 225: VISIT 6 (6 months post 3rd vac.)
|
At Day 225
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-LPS S. Sonnei Serum IgG Geometric Mean Concentration (GMCs)
Time Frame: At baseline, at 28 days after each vaccination and at 168 days after last vaccination
|
At baseline, at 28 days after each vaccination and at 168 days after last vaccination
|
|
Number of Subjects With Seroresponse for Anti-LPS S. Sonnei
Time Frame: At 28 days after each vaccination and 168 days after last vaccination
|
Seroresponse is defined as: If half of the baseline value is greater than 25 ELISA Unit (EU) then an increase of at least 50% in the post-vaccination sample as compared to baseline [i.e.
((Post-vac minus baseline)/baseline)100% ≥ 50%].
If half of the baseline value is less or equal to 25 EU then an increase of at least 25 EU in the post-vaccination sample as compared to baseline (i.e.
[post-vac minus baseline] ≥25 EU)
|
At 28 days after each vaccination and 168 days after last vaccination
|
Number of Subjects With High Seroresponse for Anti-LPS S. Sonnei (IgG ELISA ≥121 EU)
Time Frame: At baseline, at 28 days after each vaccination and at 168 days after last vaccination
|
High seroresponse is defined as a post vaccination titer ≥X anti-LPS serum IgG units in the GSK (former Novartis) ELISA that correspond to a titer of 1:800 in the ELISA method used by Cohen et al.
To determine the value for 'X' the GSK (former Novartis) anti-LPS ELISA was calibrated against the Cohen ELISA and it was found that a concentration of 121 EU EU/mL corresponds to a titer of 1:800 in the Cohen assay
|
At baseline, at 28 days after each vaccination and at 168 days after last vaccination
|
Collaborators and Investigators
Investigators
- Principal Investigator: Odile Launay, Prof, Centre d'Investigation Clinique en Vaccinologie Cochin-Pasteur (CIC1417)
Publications and helpful links
General Publications
- Micoli F, Rossi O, Conti V, Launay O, Scire AS, Aruta MG, Nakakana UN, Marchetti E, Rappuoli R, Saul A, Martin LB, Necchi F, Podda A. Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension. Front Immunol. 2021 May 4;12:671325. doi: 10.3389/fimmu.2021.671325. eCollection 2021.
- Muturi-Kioi V, Lewis D, Launay O, Leroux-Roels G, Anemona A, Loulergue P, Bodinham CL, Aerssens A, Groth N, Saul A, Podda A. Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. PLoS One. 2016 Aug 4;11(8):e0157385. doi: 10.1371/journal.pone.0157385. eCollection 2016.
- Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Scire AS, Maugard A, Marchetti E, Zancan S, Huo Z, Rondini S, Marhaba R, Finco O, Martin LB, Auerbach J, Cohen D, Saul A, Gerke C, Podda A. Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. EBioMedicine. 2017 Aug;22:164-172. doi: 10.1016/j.ebiom.2017.07.013. Epub 2017 Jul 15.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Infections
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Enterobacteriaceae Infections
- Dysentery
- Dysentery, Bacillary
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- H03_01TP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shigellosis
-
GlaxoSmithKlineRecruiting
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdRecruiting
-
PATHUnited States Department of Defense; Johns Hopkins University Center for Immunization...Completed
-
LimmaTech Biologics AGKEMRI-Wellcome Trust Collaborative Research Program; Kenya Medical Research...Completed
-
PATHCompleted
-
International Centre for Diarrhoeal Disease Research...Karolinska Institutet; Swedish International Development Cooperation Agency...Completed
-
University of OxfordJohns Hopkins University; Walter Reed Army Institute of Research (WRAIR); KEMRI-Wellcome... and other collaboratorsNot yet recruiting
-
Intralytix, Inc.University of Maryland, BaltimoreRecruiting
-
International Centre for Diarrhoeal Disease Research...GlaxoSmithKline; University of WashingtonRecruiting
-
GSK Vaccines Institute For Global Health S.r.l.Completed
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States